Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

41. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety

Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo

2014 Health Technology Assessment (HTA) Database.

42. Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia

Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia TITLE: Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia: Comparative Clinical Effectiveness and Safety DATE: 07 March 2014 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness and safety of dutasteride and finasteride for men with benign prostatic hyperplasia? 2. What is the clinical effectiveness and safety of dutasteride versus placebo for men with benign prostatic hyperplasia? 3. What (...) is the clinical effectiveness and safety of finasteride versus placebo for men with benign prostatic hyperplasia? KEY MESSAGE Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo for the treatment of benign prostatic hyperplasia. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

43. OHTAC recommendation: Photoselective vaporization for the treatment of benign prostatic hyperplasia

OHTAC recommendation: Photoselective vaporization for the treatment of benign prostatic hyperplasia OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia Ontario Health Technology Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Ontario Health Technology Advisory Committee. OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia. Toronto: Health Quality Ontario (HQO). OHTAC recommendation. 2013 Authors' conclusions Based on the earlier analysis from the Medical Advisory Secretariat on "Energy Delivery Systems for Treatment of Benign Prostatic Hyperplasia" and further evidence from the subsequent field evaluation study, OHTAC makes

2014 Health Technology Assessment (HTA) Database.

44. Photoselective vaporization for the treatment of benign prostatic hyperplasia

Photoselective vaporization for the treatment of benign prostatic hyperplasia Photoselective vaporization for the treatment of benign prostatic hyperplasia Photoselective vaporization for the treatment of benign prostatic hyperplasia Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O'Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride J-E Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O'Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride J-E. Photoselective vaporization for the treatment of benign prostatic hyperplasia. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series (OHTAS) 13(2). 2013 Authors' conclusions For men with lower urinary tract symptoms due

2014 Health Technology Assessment (HTA) Database.

45. Management of Benign Prostatic Hyperplasia (BPH)

Management of Benign Prostatic Hyperplasia (BPH) Management of Benign Prostatic Hyperplasia - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical (...) ) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Management of Benign Prostatic Hyperplasia Published 2010; Reviewed and Validity Confirmed 2014 Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. This guideline discusses proper evaluation and management, including interventional therapy, and treatment alternatives. [pdf] Panel Members Kevin T. McVary

2014 American Urological Association

46. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475) Overview | Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | Guidance | NICE Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia Interventional procedures guidance [IPG475] Published date: January 2014 Share Save (...) Guidance The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, in January 2014. Description Benign prostatic hyperplasia (BPH) is a common condition that affects older men. It is characterised by an increase in the size of the prostate, which is caused by an increased number

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

47. [Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus]

[Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos. [Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos. [Development of quality (...) indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Paz-Valiñas L, Queiro Verdes T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Paz-Valiñas L, Queiro Verdes T. Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos.. [Development of quality

2013 Health Technology Assessment (HTA) Database.

48. Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia

Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia PVP for Treatment of Benign Prostatic Hyperplasia: OHTAC Recommendation. August 2013; pp. 1–7 1 Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia Ontario Health Technology Advisory Committee August 2013 PVP for Treatment of Benign Prostatic Hyperplasia: OHTAC Recommendation. August 2013; pp. 1–7 2 Background As an alternative to transurethral resection of the prostate (TURP), photoselective (...) vaporization of the prostate (PVP) provides a bloodless, relatively painless relief of lower urinary tract symptoms (LUTS) for men with benign prostatic hyperplasia (BPH). Following a review of the evidence on energy delivery systems for treatment of benign prostatic hyperplasia in 2006, the Ontario Health Technology Advisory Committee (OHTAC) recommended that a study be conducted to evaluate PVP in Ontario. A field evaluation * (http://www.hqontario.ca/en/documents/eds/2013/full-report-PVP.pdf

2013 Health Quality Ontario

49. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]

[Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (...) ] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Paris: Haute Autorité de Santé (HAS). 2013

2013 Health Technology Assessment (HTA) Database.

50. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil L Lower urinary tr ower urinary tract symptoms secondary to act symptoms secondary to benign prostatic h benign prostatic hyperplasia: tadalafil yperplasia: tadalafil Evidence summary Published: 23 May 2013 nice.org.uk/guidance/esnm18 pathways Ov Overview erview The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF (...) ) or the MHRA or NICE websites for up- to-date information. Key points from the evidence T adalafil is a reversible phosphodiesterase type 5 inhibitor available as an oral tablet in various strengths. In October 2012, the 5 mg tadalafil tablet (taken once daily) was granted marketing authorisation to treat signs and symptoms of benign prostatic hyperplasia in adult men. Other strength tablets (2.5 mg, 5 mg, 10 mg and 20 mg) already have marketing authorisation to treat erectile dysfunction in adult men

2013 National Institute for Health and Clinical Excellence - Advice

51. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273) Overview | Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | Guidance | NICE Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) Technology appraisal [TA273] Published date: 23 January 2013 Share Guidance NICE is unable to recommend the use in the NHS of tadalafil (...) for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology. Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

52. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

Prostate artery embolisation for benign prostatic hyperplasia (IPG453) Prostate artery embolisation for benign prostatic hyperplasia | Guidance | NICE Prostate artery embolisation for benign prostatic hyperplasia Interventional procedures guidance [IPG453] Published date: April 2013 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Interventional Procedures

53. Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia 2 Avenue du Stade de France – 93218 Saint-Denis La Plaine CEDEX, France Tel.: +33(0) 1 55 93 70 00 – Fax: 33(0) 1 55 93 74 35 – contact.seap@has-sante.fr - www.has-sante.fr INAHTA brief Title Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia Agency HAS, French National Authority for Health (Haute Autorité de Santé) 2 avenue du Stade de France – F 93218 La (...) Plaine Cedex, France Tel: + 33 (0) 1 55 93 70 00 – Fax: + 33 (0) 1 55 93 74 35, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number: 978-2-11-138068-4 http://www.has-sante.fr/portail/jcms/c_827591/fr/traitement-des-symptomes-du-bas-appareil- urinaire-lies-a-lhypertrophie-benigne-de-la-prostate-par-laser-rapport-devaluation- technologique Aim To assess and compare the efficacy, the safety and the cost of the laser techniques most widely used in France (laser photoselective vaporisation

2013 Haute Autorite de sante

54. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. Full Text available with Trip Pro

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates.Post hoc analysis of four year, double blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study1617 men randomised to dutasteride or placebo with a prostate size >40 mL (...) and baseline International Prostate Symptom Score (IPSS) <8. Subjects who took medications for benign prostatic hyperplasia were excluded at study entry.Placebo or dutasteride 0.5 mg daily.Comparison of risk of clinical progression of benign prostatic hyperplasia at four years (defined as a ≥ 4 point worsening on IPSS, acute urinary retention, urinary tract infection, or surgery related to benign prostatic hyperplasia).825 participants took placebo, 792 took dutasteride. A total of 464 (29%) experienced

2013 BMJ Controlled trial quality: predicted high

55. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial

Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart (...) hyperplasia (benign enlargement of the prostate gland) versus tamsulosin monotherapy, dutasteride monotherapy or watchful waiting. The authors concluded that combination therapy was cost-effective at a willingness-to-pay threshold at or above EUR 6,000. The analysis used a conventional cost-effectiveness framework, but some aspects were not reported in detail. The authors’ conclusions appear valid but an incremental analysis among strategies compared would have been useful. Type of economic evaluation

2012 NHS Economic Evaluation Database.

56. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority)

Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

57. Silodosin - benign prostatic hyperplasia

Silodosin - benign prostatic hyperplasia Common Drug Review CDEC Meeting – March 21, 2012 Notice of CDEC Final Recommendation – April 19, 2012 Page 1 of 4 © 2012 CADTH CDEC FINAL RECOMMENDATION SILODOSIN (Rapaflo – Watson Pharma Company) Indication: Prostatic Hyperplasia, Benign Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that silodosin not be listed. Reason for the Recommendation: In the systematic review, the one double-blind randomized controlled trial (RCT (...) ) that included an active comparator reported that silodosin was non-inferior to tamsulosin, based on reductions in the International Prostate Symptom Score (IPSS); however, at the confidential submitted price, silodosin is more costly than tamsulosin controlled release (CR) and a number of other alpha blockers. Background: Silodosin has a Health Canada indication for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is an alpha 1A receptor antagonist available as 4 mg and 8 mg

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

58. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost (...) -effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Verheggen BG, Lee R, Lieuw On MM, Treur MJ, Botteman MF, Kaplan SA, Trocio JN Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2012 NHS Economic Evaluation Database.

59. Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis

Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

60. Venous thromboembolism after surgery for benign prostatic hyperplasia (Abstract)

Venous thromboembolism after surgery for benign prostatic hyperplasia A systematic review has been performed on venous thromboembolism after surgery for benign prostatic hyperplasia. The risk of deep vein thrombosis is two to four times higher after open surgery than after transurethral resection. The risk after the newer transurethral methods (laser, radiofrequency, heat) is not known. Specific studies on thromboprophylaxis are few and have limited numbers of patients. Nonetheless

2011 EvidenceUpdates